{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:37:41Z","timestamp":1783953461774,"version":"3.55.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journalofclinicalvirology.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jcv.2015.07.008","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T17:57:07Z","timestamp":1436378227000},"page":"43-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Natural prevalence of resistance-associated variants in hepatitis C virus NS5A in genotype 3a-infected people who inject drugs in Germany"],"prefix":"10.1016","volume":"70","author":[{"given":"Andreas","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Siemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svenja","family":"Groten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Stefan","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Scherbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Timm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2015.07.008_bib0005","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.07.008_bib0010","doi-asserted-by":"crossref","unstructured":"Christoph Sarrazin, Thomas Berg, Peter Buggisch, Matthias Dollinger, Holger Hinrichsen, Harald Hofer, Dietrich H\u00fcppe, Michael Manns, Stefan Mauss, J\u00f6rg Petersen, Karl-Georg Simon, Ingo van Thiel, Heiner Wedemeyer, Zeuzem1 S. 2015. Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C. Addendum zur Hepatitis C Leitlinie.","DOI":"10.1055\/s-0034-1399322"},{"key":"10.1016\/j.jcv.2015.07.008_bib0015","first-page":"275","article-title":"Virushepatitis C im Jahr 2013","volume":"2014","author":"Schink","year":"2014","journal-title":"Epidemiologisches Bull."},{"key":"10.1016\/j.jcv.2015.07.008_bib0020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.meegid.2004.08.001","article-title":"The hepatitis C virus epidemic among injecting drug users","volume":"5","author":"Pybus","year":"2005","journal-title":"Infect. Genet. Evol.: J. Mol. Epidemiol. Evol. Genet. Infect. Dis."},{"key":"10.1016\/j.jcv.2015.07.008_bib0025","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jmv.21631","article-title":"Hepatitis C virus recombinants are rare even among intravenous drug users","volume":"82","author":"Viazov","year":"2010","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jcv.2015.07.008_bib0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.12.020","article-title":"Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors","volume":"57","author":"Hernandez","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jcv.2015.07.008_bib0035","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2015.07.008_bib0040","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2015.07.008_bib0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/jvh.12271","article-title":"Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1","volume":"22","author":"Kosaka","year":"2015","journal-title":"J. Viral hepatitis"}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138665321500298X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138665321500298X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T03:01:07Z","timestamp":1566961267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138665321500298X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":9,"alternative-id":["S138665321500298X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2015.07.008","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural prevalence of resistance-associated variants in hepatitis C virus NS5A in genotype 3a-infected people who inject drugs in Germany","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2015.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}